Jasper Therapeutics, Inc. — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Jasper Therapeutics (Parent) agreed to merge with Kira Pharmaceuticals (Company, a Cayman Islands company) via merger subsidiary Kira Holdco. Jasper will issue 5,587,800 shares of voting common stock (capped at 19.9% of outstanding shares pre-closing) plus up to 4,996,178 convertible preferred shares (convertible at 61:1 ratio) to Kira shareholders and option/SAFE holders. Kira shareholders comprise 27.67M ordinary shares and 3.66M preferred shares outstanding as of signing (July 16, 2026). Deal includes concurrent PIPE investment in Jasper convertible preferred stock and CVR issuance to existing Jasper shareholders. Closing expected within 120 days; shareholder votes required from both companies.
Why this rating
Material reverse-merger structure materially dilutes Jasper shareholders (19.9% stake to Kira holders; additional dilution via convertibles), but relative to $74.8M market cap and biotech stage, deal scale is significant. Governance/board changes included. Not transformational alone but meaningful capital structure shift.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.